<DOC>
	<DOC>NCT00073034</DOC>
	<brief_summary>EAA-090 is being developed for the treatment of neuropathic pain associated with diabetic neuropathy. It is a selective antagonist that binds competitively to the glutamate site of the N-methyl-D-aspartate (NMDA) receptor. This study will assess the safety and efficacy of 3 fixed oral doses of EAA-090 compared with placebo in subjects with neuropathic pain associated with diabetic neuropathy.</brief_summary>
	<brief_title>Study Evaluating EAA-090 in Adult Outpatients With Neuropathic Pain Associated With Diabetic Neuropathy</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Peripheral Nervous System Diseases</mesh_term>
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Diabetic Neuropathies</mesh_term>
	<criteria>Women of childbearing potential must have a negative serum pregnancy test result at screening Diabetes mellitus (type I or II) that is controlled by oral or parenteral hypoglycemic agents or diet Diagnosis of painful diabetic distal symmetric sensory/motor polyneuropathy Pregnancy, lactation, or plans to become pregnant during the study DepoProvera or oral contraceptives that have been taken for less than 1 month before study day 1 if not using another medically accepted form of birth control History of multiple drug allergies that may put the subject at greater risk during study participation in the opinion of the investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Neuropathic Pain</keyword>
	<keyword>Diabetic Neuropathy</keyword>
</DOC>